RE:reading material In preclinical trials, TLD-1433, when activated by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells.
In a 2017, Company news release, Dr. Pavel Kaspler, PhD, Theralase Research Scientist stated that, “Radiation therapy followed by NIR laser light activation of TLD-1433 is a new and unexpected discovery by the members of our research team under the leadership of Dr. Arkady Mandel and Dr. Lothar Lilge. This discovery has far reaching implications, including: targeting cancers that are difficult, if not impossible to reach with conventional laser light sources, such as GBM brain tumours or deep tissue related cancers.”
Advantages of TLD-1433:
- Stable under radiation activation and remains able to produce ROS via subsequent NIR laser light activation
- Able to be activated by radiationeliciting a PDT-like cell kill
- Able to be dually activated (radiationfollowed by NIR laser) delivering a cell kill greater than the two technologies applied separately
- Able to destroy cancer cells predominantly via necrosis at 24 hours post treatment.
- Able to deliver noticeable damage to tumors when radiationactivated
- Able to deliver significant tumour damage when dually activated (radiationfollowed by NIR laser) in the presence of transferrin
https://theralase.com/anti-cancer-therapy/research-publications/#publications